Funding Opportunities--Dystonia
Dystonia Medical Research Foundation
All Regions
12/15/2008
$130,000

Funding Opportunities

The Dystonia Medical Research Foundation (DMRF) encourages and supports research related to the causes, mechanisms, prevention, and treatment of all forms of dystonia, the third most common movement disorder. Through a peer-review process, all applications are reviewed and ranked by the DMRF’s Medical and Scientific Advisory Council, who then make recommendations to the Board of the Directors for funding.

Types of Awards

Fellowships
A two-year Fellowship is designed to assist post-doctoral fellows establish careers in research relevant to dystonia.

The DMRF supports hypothesis-driven research at the genetic, molecular, cellular, systems, or behavioral levels that may lead to a better understanding of the pathophysiology of dystonia or to new therapies for dystonia.

Funding for fellowships is $50,000 per year for two years.

Research Grants
Research grants are available in support of hypothesis-driven research at the genetic, molecular, cellular, systems, or behavioral levels that may directly or indirectly lead to a better understanding of the pathophysiology and to new therapies for any or all forms of dystonia. Although early-onset primary generalized dystonia is of special interest, we also support studies on the focal dystonias, including laryngeal dystonia/spasmodic dysphonia, as well as secondary dystonias.

Funding for grants is available up to $65,000 per year for 1 or 2 years.

The deadline for grant and fellowship applications is December 15, 2008. Applications and guidelines will be available September 15.

Dystonia Medical Research FoundationNational Headquarters
One East Wacker Drive, Suite 2810
Chicago, Illinois 60601-1905
Phone: 312-755-0198
Toll free: 800-377-DYST (3978)
In Canada: 800-361-8061
Fax: 312-803-0138
Email: dystonia@dystonia-foundation.org

Behavioral Scientist, Cell Biologist, Molecular Biologist , Neurologist, Physician Researcher, Young Investigator, Young Scientist
2009 McKnight Scholar Awards for Neuroscience
McKnight Endowment Fund for Neuroscience
All Regions
01/02/2009
$225,000
2009 McKnight Scholar Awards

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To this end, The McKnight Endowment Fund for Neuroscience invites applications for the 2009 McKnight Scholar Awards.

These awards were established to encourage emerging neuroscientists to focus on disorders of learning and memory. Applicants for the McKnight Scholar Awards must demonstrate interest in solving important problems in relevant areas of neuroscience, including the translation of basic research to clinical neuroscience. Awards are given to exceptional young scientists who hold the M.D. and/or Ph.D. degree and who are in the early stages of establishing an independent laboratory and research career. Traditionally, successful candidates have held faculty positions for at least one year. For the names of previous recipients and their projects, click here.

Up to six McKnight Scholars each will receive three years of support, beginning July 1, 2009.

Eligibility. Applicants must have the following:

* M.D. and/or Ph.D. degree; formal postdoctoral training completed at the time of application.
* A record of meritorious research in areas pertinent to the interests of the Endowment Fund.
* Not more than four years of experience in an independent/tenure-track faculty position (exceptions may be made to account for parental leave).
* Evidence of a commitment to a career in neuroscience.
* U.S. citizenship or lawful permanent resident status.
* U.S.-based sponsoring institution, to which awards will be paid.

Applicants may not:

* Be employees of the Howard Hughes Medical Institute or scientists within the intramural program of the National Institutes of Health.
* Apply in more than two rounds of competition.
* Apply for continued postdoctoral support.
* Hold tenured positions or their equivalent.
* Hold another type of McKnight Endowment Fund for Neuroscience award that would overlap with the Scholar Award.

Amount and Purpose of Support. Each McKnight Scholar will receive $75,000 annually in 2009, 2010, and 2011. Funds may be used in any way that will facilitate development of the Scholar’s research program, but not for indirect costs.

Selection Process. A review committee will evaluate applications and invite a select few to interview with the committee. Applicants selected will be notified by March 20, 2009. The interviews are scheduled for Friday, April 17, 2009, in San Francisco. The committee then will recommend candidates to the Board of Directors of the Endowment Fund for final decision. Awards will be announced on or before May 15, 2009.

Printed application forms and guidelines. Please call, email, or write the office of The McKnight Endowment Fund for Neuroscience.

Completed applications must arrive no later than January 2, 2009.

The McKnight Endowment Fund for Neuroscience
710 South Second Street, Suite 400
Minneapolis, Minnesota 55401
info@mcknight.org
www.mcknight.org/neuroscience
Neurologist, Neuroscientist, Physician Researcher, Young Investigator, Young Scientist
Student Fellowship--Myasthenia Gravis or Related Neuromuscular Conditions
Myasthenia Gravis Foundation of America
All Regions
03/15/2009
$5,000

Student Fellowship--Myasthenia Gravis or Related Neuromuscular Conditions

These fellowships are awarded annually to current medical students
or graduate students interested in the scientific basis of myasthenia
gravis or related neuromuscular conditions, serving both to further
scientific inquiries into the nature of these disorders and to
encourage more research. The stipend is up to $5,000.

Annual deadline for applications is March 15.

Myasthenia Gravis Foundation of America
1821 University Ave. W., Suite S256
St. Paul, MN 55104

Telephone: (651)917-6256 or (800)541-5454

Fax: (651)917-1835

Doctoral Student, Graduate Student, Medical Student
Request for Applications--Niemann-Pick Type C (NP-C) disease
Ara Parseghian Medical Research Foundation
All Regions
02/13/2009
$250,000

Ara Parseghian Medical Research Foundation

Request for Applications--Niemann-Pick Type C (NP-C) disease

Niemann-Pick Type C (NP-C) disease is a genetic, neurodegenerative disorder which causes progressive deterioration of the nervous system. It usually affects children by interfering with their ability to metabolize cholesterol. Adult onset may also occur. Large amounts of cholesterol accumulate within the liver, spleen, and brain. This metabolic disorder leads to a series of neurological problems that are ultimately fatal...until a treatment is found!

POTENTIAL APPLICANTS PLEASE NOTE: If you have never received funding from the APMRF, please submit electronically a Letter of Intent as outlined below. This procedure will allow our Scientific Advisory Board to read a brief summary of your proposed research without you having to submit the full grant application.

Please have this letter addressed to the APMRF Scientific Advisory Board to the Foundation office by February 13, 2009. Send the Letter of Intent as an ATTACHMENT to Glen Shepherd, Executive Director: gshepherd@parseghian.org

Our SAB will review all Letters of Intent. You will be notified by April 1 whether or not the SAB would like for you to submit the full grant application for consideration of funding. The full grant applications are due no later than April 30, 2009.
The Letter of Intent should not exceed 2 pages of text (12 font single spaced) and must include the following information in this order:

1. Your name, position, title, institution, address, phone and E-mail address
2. Title of proposed research study
3. The objective of the study and hypothesis to be tested
4. The relevance to Niemann-Pick Type C disease (an extensive literature review is not required)
5. Preliminary data (this is encouraged but not essential)
6. A statement of the methods to be used and a brief description of how the results will be evaluated
7. Estimated amount of award you are requesting and whether for a one- or two-year period
8. Current financial support: List each current grant or contract you have that would overlap with the conduct of this research and how this overlap will be accommodated if APMRF funding is awarded. If there are no such grants, state “NONE”

If you have questions or comments on the Letter of Intent, please contact Glen Shepherd at (520) 577-5106 or gshepherd@parseghian.org

Neurologist, Neuroscientist, Scientist
Coins for Alzheimer's Research Trust
The CART Fund, Inc.
All Regions
12/01/2008
$250,000
The CART Fund, Inc.
Coins for Alzheimer's Research Trust

The Rotary clubs in the states of Georgia and the two Carolinas as well as a number of individual clubs throughout the United States, with the assistance from the American Federation of Aging Research, established in 1996 a new funding program called The CART Fund. The fund has already distributed a total amount of approximately $2,300,000 through grants to ten University Research Centers listed below.

The goal of the fund is to encourage exploratory and developmental AD research projects by providing support for the early and conceptual plans of those projects that may not yet be supported by extensive preliminary data but have the potential to substantially advance biomedical research. This proposal should be distinct from those projects designed to increase knowledge in a well established area unless it is intended to extend previous discoveries toward new directions or applications.

The Rotary CART Fund is inviting interested applicants to submit a LETTER-of-INTENT that includes sufficient detail to communicate the importance of your study as well as information on its feasibility.

Applications may encompass a project period of up to two years with a combined budget for direct cost up to $250,000. No indirect costs are allowed. Domestic public and private institutions are eligible, such as universities, colleges, hospitals and laboratories. This is for NEW projects only. Applications will be deemed ineligible from for-profit organizations as well as those already supported by regular or program grants. Up to two $250,000 awards will be made in 2009.

Dr. John Trojanowski will chair a scientific review group that will triage the letters-of-intent and select a maximum of fifteen deemed to have the highest merit. Those selected will be invited to submit a subsequent standard grant application from which the final recommendation will be made by the review group. The final selection will be made by the CART Fund selection committee

Please submit a letter-of-intent as a PDF file by December 1, 2008. The letter should include the following:

Contact information
A statement containing: the hypothesis of the project; the specific aims; a description of the experimental design, methods and model systems; a statement giving future directions this research could lead including a reference to the health relationship of the project [2 pg. limit].
A biographical statement of the principal investigator [2 pg. limit].
Notifications of the finalists (maximum of 15) will be mailed by January 7, 2009. Investigators whose proposals are accepted for further consideration will be sent a full application form which must be completed and returned by February 16, 2009.

Submit e-mail questions and letters-of-intent to Dr. James B. Puryear, Chairman, CART Grants Program: jimpuryear@comcast.net
Neurologist, Physician Researcher, Scientist
Therapeutics Development Initiative 2009
Michael J. Fox Foundation for Parkinson’s Research
All Regions
01/20/2009
$0

Therapeutics Development Initiative 2009
Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ET

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.
Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company.

Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease.

Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application.

MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly.

Conference Call
MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.

While there are no restrictions as to the specific approaches to be studied under this RFP,
successful applications are most likely to focus on at least one of the following categories:
o Neuroprotective strategies focused on slowing or preventing the process of neuronal
death.
o Neuroregenerative strategies to restore or replace neuronal function.
o Novel drug delivery mechanisms and/or surgical procedures.
o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD,
including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression
among others.
o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias,
etc.

If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address:

The Michael J. Fox Foundation for Parkinson's Research
Church Street Station
P.O. Box 780
New York, NY 10008-0780

Clinical Pharmacist, Neurochemist, Neurologist, Neuroscientist, Scientist
Prize4Life Biomarker Prize - Second Track--Amyotrophic Lateral Sclerosis
Prize4Life
All Regions
11/06/2008
$1,000,000
Prize4Life announced its 2-year $1 million ALS/MND Biomarker Challenge on November 6, 2006.

The Prize4Life Biomarker Prize is divided into two tracks - theoretical findings and real outcomes.

The first track was a call for scientists and researchers from all backgrounds to submit theoretical papers on how they would develop a biomarker for ALS. In May 2007, Prize4Life awarded $15,000 for each of the five best ideas submitted . This track is now closed for submissions.

The second track, currently running, involves identifying an actual ALS biomarker. Anyone can submit a solution to the second track at any time, regardless of whether they participated in the first track.

A prize of up to $1,000,000 will be awarded in track two for the first validated ALS biomarker submitted that meets the desired requirements. Those submitting a solution must provide statistically significant results as proof of the validity of the solution. This challenge will end in November 2008 if a winning solution is not received so send in your solution now!!

A biomarker is a distinctive biological or biologically derived indicator that can mark the presence and/or progression of a disease. A biomarker can take the form of a chemical marker, a mechanical device that measures relevant physiological changes, or combination of the two. Currently, there are no known biomarkers for ALS for either diagnosing or measuring the progression of the disease.

Interested scientists and researchers should REGISTER with Prize4Life.

INNOCENTIVE 4470259
ALS Biomarker
POSTED: NOV 06, 2006
DEADLINE: NOV 06, 2008
$1,000,000 USD
Biochemist, Cell Biologist, Molecular Biologist , Neurologist, Neuroscientist, Physician Researcher
International Society for Neurochemistry Support for Conferences
International Society for Neurochemistry
All Regions
10/31/2008
$20,000

International Society for Neurochemistry Support for Conferences

The ISN Conference Committee (ISN-CC) provides financial support for the organisation of small conferences on specialised neurochemical topics and sponsors neurochemistry symposia within meetings of other scientific societies or groups. Applications are examined by the ISN-CC and are granted on a competitive basis according to these guidelines. The final decision on the funding of awards is made by the Chair of ISN-CC.

Inquiries and formal applications, which may be submitted twice a year (before April 30 or October 31), should be sent by Email to: Prof. Ralf Dringen (Chairman of ISN-CC, ralf.dringen@uni-bremen.de).

General information on ISN-CC support:

1) A conference/symposium supported by ISN-CC should deal with an important and up-to-date topic of neurochemistry. Applicants should justify why their conference is important in the research area of neurochemistry and why ISN should support their conference.

2) The conference/symposium supported should be international (preferably intercontinental) as reflected by the composition of the organising committee, the list of prospective invited speakers and the countries of origin of the expected attendees. Local conferences will not be supported.

3) For applications the forms provided on the ISN homepage should be used. All required information should be carefully provided. A detailed budget for the conference should be included and a clear statement of how the support requested from ISN-CC will be spent.

4) The application must be received by the ISN-CC Chairperson by either of the deadlines (April 30 and October 31) and the activity should be held at least four months after the deadline and within a year of application submission.

5) ISN-CC strongly discourages application for support of a second consecutive conference/workshop in a series of meetings, or workshops that are organised by one society, one organizer or a group of organizers. Priority for funding will be given to conferences that have not previously received ISN-CC support. Applicants (organisers, groups of or ganisers or Societies) are required to declare if they have received previous ISN-CC support.

6) In the case of approval, the applicant(s) will receive 80% of the amount granted before the meeting. Upon approval of an application the funds must be sent to a bank account of the applicant’s institution or a designated bank account associated with the meeting. Transfer to any private bank account is not possible. The residual 20% will be transferred upon receipt of the meeting report and approval of the report by the chairperson of the ISN-CC.

7) Conferences that are supported by ISN-CC, as well as reports on ISN supported conferences, will be publicized on the ISN homepage (www.neurochemistry.org).

8) Conference organisers or chairs of supported symposia agree to submit a meeting report to the CC Chairperson within one month after the end of the meeting. The residual 20% of support will only be available and transferred if an acceptable report is received in time by the chairperson of ISN-CC.

Support for small conferences on neurochemical topics:

1) The ISN-CC provides financial support for the organisation of small conferences on specialised neurochemical topics. The conference supported should deal with an important and up-to-date topic of neurochemistry.

2) ISN-CC provides support of up to US $ 20,000 for a small conference.

3) At least 60% of the money granted is expected to be used as Young ISN Neurochemistry Awards to facilitate the attendance of young neurochemists (postdocs and students) at Small Neurochemical Conferences. The name and institutional affiliation of the ISN awardees should be listed in the meeting’s brochure and in the post-meeting report.

ISN Symposium in a conference of another society or scientific group:

1) The ISN Symposium should deal with an important and up-to-date topic of neurochemistry.

2) A symposium is a session within a meeting that normally consists of 3 to 5 presentations. Applications for support of full short meetings or satellite meetings are not considered for ISN symposium support. The application should list the title of the symposium, the names of the speakers, the titles of the presentations and at least 2 recent publications of each speaker that are relevant to the topic of the symposium.

3) Applicants can apply for up to US $ 7,000 for an ISN Symposium.

4) Funds should be used to cover travel, registration and accommodation expenses of speakers. Travel will only be supported at the level of advanced excursion rates. Expenses for honoraria, food, social events etc. will not be funded.

5) Only one ISN symposium per conference will be supported by ISN-CC.

6) A symposium supported by ISN in a meeting of another society or scientific group must be designated as an ISN Symposium and advertised in the conference material.

7) With the application, a letter of support from the chairperson of the Organising Committee of the conference should be submitted. This letter should state that the ISN-Symposium of the applicant will be included into the program as ISN-Symposium, if the application is successful.

Additional Guidelines for Applicants to ISN-CC:

Application for ISN-CC support will not be considered, if:

1) an application is received after the deadline (April 30 and October 31).

2) the conference applied for commences within four months after the deadline for applications.

3) the application does not sufficiently justify how the conference/symposium addresses an important and up-to-date topic of neurochemistry and why it should be supported by ISN.

4) the application does not contain a detailed budget that clearly states how the requested money will be spent according to the regulations of ISN-CC.

5) the application is for support of a satellite conferences of the ISN Biennial International Meetings. These meetings are supported from a different fund. In this case, applications are considered by the Chairperson of the ISN Meeting Program Committee.

6) the application is for support of an Annual and Biennial Meeting of the sister societies ASN, ESN and APSN. These meetings receive support from other ISN funds.

7) the applicant is a member of the ISN Council or the ISN-CC.

8) the applicant has applied or will apply for support from other ISN funds for the same conference (for example CAEN or other ISN-funded initiatives).

Address any enquiries by email to:

Dr. Ralf Dringen
Chair, ISN-CC
ralf.dringen@uni-bremen.de

Medicinal Chemist, Neurochemist, Neurologist, Neuroscientist
John Dystel Fellowship in Multiple Sclerosis
National Multiple Sclerosis Society
All Regions
02/09/2009
$44,000
John Dystel Fellowship in Multiple Sclerosis

This program, sponsored by the National MS Society and supported by the John Dystel Fellowship Fund, is designed for registered nurses interested in receiving advanced training in MS nursing care. The fellow will practice in a specialized MS clinical setting under the tutelage of an MS nurse expert. Training consists of supervised patient care, exposure to multidisciplinary treatment, and other instructional activities. The program offers candidates two options: a three-month fellowship or a six-month fellowship.

The preferred candidate will hold a bachelor's degree. It is the responsibility of the applicant to arrange the proposed training with an appropriate mentor and institution, prior to formal application. The award for the three-month option is $22,500; the award for the six-month option is $44,000. The award includes the fellow's salary, benefits, and participation in education activities; a $4,000 honorarium for the mentor; and indirect costs (not to exceed 10% of the award).

Completed applications, including all required supporting documents, must be received at the Society by February 9, 2009.
Notification of award will take place by April 20, 2009.
The fellowship will begin June 1, 2009. (Alternate start dates will be considered)
Neuroscience Nurse, Nurse
Sanofi-Aventis Minority Scholars Program
American Academy of Neurology/Aventis Pharmaceuticals
All Regions
11/03/2008
$2,200
sanofi-aventis Minority Scholars Program
Application deadline: November 3, 2008

Applications will be available mid-August.

Recipient will receive:
$2,200 travel stipend to attend the American Academy of Neurology (AAN) 61th Annual Meeting in Seattle, WA, April 25 - May 2, 2009
Annual Meeting complimentary registration for the meeting
Educational programs at the junior member rate

Eligibility:
Racial minority medical students from under-represented and underserved populations in good standing at a US medical school. Preference is given to second- and third-year students.

Application Requirements:
A single-spaced, one-page essay outlining the applicant's interest in a career in neurology, their commitment to serve underrepresented communities, and a statement on how the applicant would use their Annual Meeting opportunity.
A letter of recommendation from a neurology professor.
A curriculum vitae.
For more information about the sanofi-aventis Minority Scholars Program, please contact Lucy Persaud at lpersaud@aan.com or (651) 695-2741.

The sanofi-aventis Minority Scholars Program is funded by an educational grant from Aventis Pharmaceuticals.
African-American, Latino/Hispanic, Medical Student, Minority Member, Native American

23456next